Changes

* '''[http://www.ccga.io/index.php/Acute_lymphoblastic_leukaemia_(ALL) Acute Lymphocytic Leukemia (ALL)]'''

* '''[http://www.ccga.io/index.php/Acute_lymphoblastic_leukaemia_(ALL) Acute Lymphocytic Leukemia (ALL)]'''

The t(12;21)(p13;q22) resulting in ETV6-RUNX1 fusion has been found in 25% of childhood B-cell acute lymphoblastic leukemia (B-ALL), but are much less common in adult B-ALL (only 2%) [2].  The fusion protein produced by the translocation confers a dominant negative effect on the normal RUNX1 protein, resulting in transcriptional activation become transcriptional repression (1,2].  The t(12;21) confers a favorable prognosis with cures seen in >90% of childhood B-ALL [1].

The t(12;21)(p13;q22) resulting in ETV6-RUNX1 fusion has been found in 25% of childhood B-cell acute lymphoblastic leukemia (B-ALL), but are much less common in adult B-ALL (only 2%) [2].  The fusion protein produced by the translocation confers a dominant negative effect on the normal RUNX1 protein, resulting in transcriptional activation become transcriptional repression [1,2].  The t(12;21) confers a favorable prognosis with cures seen in >90% of childhood B-ALL [1].

* '''[http://www.ccga.io/index.php/Chronic_Myelomonocytic_Leukemia_(CMML) Chronic Myelomonocytic Leukemia (CMML)]''''

* '''[http://www.ccga.io/index.php/Chronic_Myelomonocytic_Leukemia_(CMML) Chronic Myelomonocytic Leukemia (CMML)]''''